Novartis, Par Hit With Pay-For-Delay Suit Over Exforge
Novartis Pharmaceuticals Corp. was able to keep a generic of its hypertension drug Exforge off the market for years by agreeing to let Par Pharmaceutical Inc. have six months of generic...To view the full article, register now.
Already a subscriber? Click here to view full article